"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Macy’s is investigating how hundreds of millions of dollars were hidden by one employee. The retailer delayed its quarterly ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...

In fact, Viking just gave investors an update which firms up its status as a very promising company. Here's what it reported, ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.